Key result
Subclinical autonomic dysfunction was present in 80% of patients with advanced lymphoma at presentation, with significant improvement in autonomic scores following chemotherapy.
Why the study?
Does combination chemotherapy improve cardiovascular autonomic function in patients with advanced lymphoma?
Cohort (n=20)
Does combination chemotherapy improve cardiovascular autonomic function in patients with advanced lymphoma?
Subclinical autonomic dysfunction is highly prevalent in patients with advanced lymphoma and improves with chemotherapy, suggesting a paraneoplastic etiology.
Answers are grounded in this paper and cite their sources.
Supports autonomic screening in advanced lymphoma; leaves open chemotherapy's causal role versus paraneoplastic resolution.
A prospective study was carried out to determine the prevalence of autonomic dysfunction in patients with lymphoma, and to assess the effect on this of chemotherapy. Twenty consecutive patients presenting with Hodgkin's disease, high-grade non-Hodgkin's lymphoma, or low-grade non-Hodgkin's lymphoma were studied. All had advanced disease, requiring combination chemotherapy which included the use of vinca alkaloids. Clinical assessment and standard cardiovascular autonomic function tests were carried out prior to and following completion of chemotherapy. Although no patients had clinical evidence of autonomic neuropathy at presentation, 16 (80%) had abnormal cardiovascular autonomic function tests. There was no correlation with the presence or absence of mediastinal disease. There was significant improvement in autonomic scores with treatment despite the use of drugs of known neurological toxicity. Some patients showed residual abnormalities of autonomic function despite disease resolution. We suggest that subclinical autonomic dysfunction is common in patients with lymphoma, and probably represents a paraneoplastic syndrome--the pathogenesis and prevalence of which deserve further study. This phenomenon may predispose patients with lymphoma to develop gastrointestinal and genitourinary dysfunction, or postural hypotension, and should be considered during the evaluation of the neurotoxicity of chemotherapy regimens.
No takes yet. Share an insight, caveat, or question.
Turner et al. (1993) conducted a cohort in Hodgkin's disease and non-Hodgkin's lymphoma (n=20). Combination chemotherapy including vinca alkaloids vs. Pre-chemotherapy baseline was evaluated on Abnormal cardiovascular autonomic function tests at presentation. Subclinical autonomic dysfunction was present in 80% of patients with advanced lymphoma at presentation, with significant improvement in autonomic scores following chemotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: